

REMARKS

The above amendments under Section 1.312 to the specification are being made to correct the priority information within the specification. This amendment is being submitted along with a petition under 1.78(a)(3). The amendment is needed to provide full disclosure of the correction to the priority information as indicated in the accompanying petition.

Entry of the amendment prior to granting of the patent is respectfully requested.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

/mary k. vanatten, reg. no. 39,408/
Mary K. VanAtten
Attorney for Applicant
Reg. No. 39,408
Phone: 609-252-4379

Date: May 16, 2007